Effect of pioglitazone on the abrogated cardioprotective effect of ischemic preconditioning in hyperlipidemic rat heart | Zendy

HarlokeshNarayan Yadav | Zendy; Dhiraj Mittal | Zendy; Rajeev Taliyan | Zendy; PL Sharma | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Effect of pioglitazone on the abrogated cardioprotective effect of ischemic preconditioning in hyperlipidemic rat heart

Author(s) -

HarlokeshNarayan Yadav,

Dhiraj Mittal,

Rajeev Taliyan,

PL Sharma

Publication year - 2016

Publication title -

indian journal of pharmacology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.286

H-Index - 59

eISSN - 1998-3751

pISSN - 0253-7613

DOI - 10.4103/0253-7613.174545

Subject(s) - pioglitazone , cardioprotection , wortmannin , ischemic preconditioning , medicine , pharmacology , lactate dehydrogenase , ischemia , perfusion , endocrinology , pi3k/akt/mtor pathway , chemistry , diabetes mellitus , apoptosis , type 2 diabetes , biochemistry , enzyme

The signaling pathways upstream of glycogen synthase kinase-3β (GSK-3β) get reduced during ischemic preconditioning (IPC) in hyperlipidemic rat heart. Pioglitazone, an insulin sensitizer, exerts cardioprotection through GSK-3β. The objective of the study is to investigate the role of pioglitazone on the attenuated cardioprotective effect of IPC in hyperlipidemic rat heart.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research